Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 798

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 798
---
 ended on December 31, 
                       2024 |     | 2023 |     | 2022 |
|:------------------------------------------------------------|:----|---------------------------:|:----|-----:|:----|-----:|
|                                                             |     |           USD in thousands |     |      |     |      |
| Total expense arising from share-based payment transactions |     |                        208 |     |  149 |     |  235 |

B. Share-based payment plan On March 28, 2022, the Company’s Board of Directors adopted a new global options plan as part of the decision to evaluate the listing of the Company’s shares on the Nasdaq Capital Market. The new plan is intended for the Company’s employees, consultants, service providers, and officers (including directors) (hereinafter, the “New Plan”). The New Plan allows non -marketableoptions (hereinafter, the “Options”) that can be exercised for the Company’s shares to be granted at different exercise prices, as well as restricted share units. The New Plan entered into force on the day of its adoption by the Board of Directors, subject to the required submission to the tax authorities, in accordance with the law. The New Plan will expire at the end of 10 years from the aforementioned date. C.On March 10, 2021, the general meeting of the shareholders approved the grant of Options to the Company’s former Chief Executive Officer (the “CEO”) as part of his employment agreement, as well as to the current chairman of the Company’s Board of Directors as part of the engagement agreement, according to which 500,000 Options were granted to the Company’s CEO, each of which is exercisable into one Share. The exercise price of the Options will be as follows: 300,000 options at an exercise price of USD $0.7 (NIS 2.3), 150,000 options at an exercise price of USD $1 (NIS 3), and 50,000 options at an exercise price of USD $1.7 (NIS 5). The vesting period of the Options is three years, wherein one -thirdof the Options are to mature after 1 year and the remaining Options are to mature linearly over eight quarters. The Options were granted in the equity track under section 102 under the Company’s standard conditions and in accordance with the Company’s option plan. The Options will be exercisable for a period of 5 years from their grant